Cellular mechanisms for diastolic dysfunction in the human heart

Current Pharmaceutical Biotechnology

Volumn 13, Issue 13, 2012, Pages 2532-2538

  Czuriga, Dániel ^a,b   Paulus, Walter J ^b   Czuriga, István ^a   Édes, István ^a   Papp, Zoltán ^a   Borbély, Attila ^a,b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiomyocytes; Contractile dysfunction; Diabetes mellitus; Diastole; Fibrosis; Human heart

Indexed keywords

ALPHA GALACTOSIDASE; ANGIOTENSIN II; COLLAGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLYCOSPHINGOLIPID; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE;

AGING; AORTA VALVE STENOSIS; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; FABRY DISEASE; GENE MUTATION; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART LEFT VENTRICLE RELAXATION; HEART MUSCLE FIBROSIS; HEART VENTRICLE OVERLOAD; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TISSUE DOPPLER IMAGING;

AGING; AORTIC VALVE STENOSIS; DIABETIC CARDIOMYOPATHIES; DIASTOLE; FABRY DISEASE; FIBROSIS; GLYCOSPHINGOLIPIDS; HEART FAILURE, DIASTOLIC; HUMANS; MYOCARDIUM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84871462659     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112804583005     Document Type: Review

References (47)

1. Lakatta, E.G.; Levy, D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation, 2003, 107(2), 346-354.
2. Gazoti Debessa, C.R.; Mesiano Maifrino, L.B.; Rodrigues de Souza, R. Age related changes of the collagen network of the human heart. Mech. Ageing Dev., 2001, 122(10), 1049-1058.
3. de Souza, R.R. Aging of myocardial collagen. Biogerontology, 2002, 3(6), 325-335.
4. Asif, M.; Egan, J.; Vasan, S.; Jyothirmayi, G.N.; Masurekar, M.R.; Lopez, S.; Williams, C.; Torres, R.L.; Wagle, D.; Ulrich, P.; Cerami, A.; Brines, M.; Regan, T.J. An advanced glycation endproduct crosslink breaker can reverse age-related increases in myocardial stiffness. Proc. Natl. Acad. Sci. USA, 2000, 97(6), 2809-2813.
5. Shapiro, B.P.; Owan, T.E.; Mohammed, S.F.; Meyer, D.M.; Mills, L.D.; Schalkwijk, C.G.; Redfield, M.M. Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines. Circulation, 2008, 118(10), 1002-1010.
6. Basso, N.; Cini, R.; Pietrelli, A.; Ferder, L.; Terragno, N.A.; Inserra, F. Protective effect of long-term angiotensin II inhibition. Am. J. Physiol. Heart Circ. Physiol., 2007, 293(3), H1351-1358.
7. Siwik, D.A.; Pagano, P.J.; Colucci, W.S. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am. J. Physiol. Cell Physiol., 2001, 280(1), C53-60.
8. Barcellos-Hoff, M.H.; Dix, T.A. Redox-mediated activation of latent transforming growth factor-beta 1. Mol. Endocrinol., 1996, 10(9), 1077-1083.
9. Saito, K.; Ishizaka, N.; Aizawa, T.; Sata, M.; Iso-o, N.; Noiri, E.; Mori, I.; Ohno, M.; Nagai, R. Iron chelation and a free radical scavenger suppress angiotensin II-induced upregulation of TGF-beta1 in the heart. Am. J. Physiol. Heart Circ. Physiol., 2005, 288(4), H1836-1843.
10. Chen, W.; Frangogiannis, N.G. The role of inflammatory and fibrogenic pathways in heart failure associated with aging. Heart Fail. Rev., 2010, 15(5), 415-422.
11. Klapholz, M.; Maurer, M.; Lowe, A.M.; Messineo, F.; Meisner, J.S.; Mitchell, J.; Kalman, J.; Phillips, R.A.; Steingart, R.; Brown, E.J. Jr.; Berkowitz, R.; Moskowitz, R.; Soni, A.; Mancini, D.; Bijou, R.; Sehhat, K.; Varshneya, N.; Kukin, M.; Katz, S.D.; Sleeper, L.A.; Le Jemtel, T.H. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J. Am. Coll. Cardiol., 2004, 43(8), 1432-1438.
12. De Keulenaer, G.W.; Brutsaert, D.L. Systolic and diastolic heart failure: different phenotypes of the same disease? Eur. J. Heart. Fail., 2007, 9(2), 136-143.
13. Brutsaert, D.L.; De Keulenaer, G.W. Diastolic heart failure: a myth. Curr. Opin. Cardiol., 2006, 21(3), 240-248.
14. van Heerebeek, L.; Borbely, A.; Niessen, H.W.; Bronzwaer, J.G.; van der Velden, J.; Stienen, G.J.; Linke, W.A.; Laarman, G.J.; Paulus, W.J. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation, 2006, 113(16), 1966-1973.
15. Borbely, A.; Papp, Z.; Edes, I.; Paulus, W.J. Molecular determinants of heart failure with normal left ventricular ejection fraction. Pharmacol. Rep., 2009, 61(1), 139-145.
16. Hernandez, A.F.; Hammill, B.G.; O'Connor, C.M.; Schulman, K.A.; Curtis, L.H.; Fonarow, G.C. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J. Am. Coll. Cardiol., 2009, 53(2), 184-192.
17. Bronzwaer, J.G.; Paulus, W.J. Diastolic and systolic heart failure: different stages or distinct phenotypes of the heart failure syndrome? Curr. Heart Fail. Rep., 2009, 6(4), 281-286.
18. Hamdani, N.; Paulus, W.J.; van Heerebeek, L.; Borbely, A.; Boontje, N.M.; Zuidwijk, M.J.; Bronzwaer, J.G.; Simonides, W.S.; Niessen, H.W.; Stienen, G.J.; van der Velden, J. Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction. Eur. Heart J., 2009, 30(15), 1863-1872.
19. Paulus, W.J.; van Ballegoij, J.J. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J. Am. Coll. Cardiol., 2010, 55(6), 526-537.
20. Borbely, A.; van der Velden, J.; Papp, Z.; Bronzwaer, J.G.; Edes, I.; Stienen, G.J.; Paulus, W.J. Cardiomyocyte stiffness in diastolic heart failure. Circulation, 2005, 111(6), 774-781.
21. Borbely, A.; van Heerebeek, L.; Paulus, W.J. Transcriptional and posttranslational modifications of titin: implications for diastole. Circ. Res., 2009, 104(1), 12-14.
22. Borbely, A.; Falcao-Pires, I.; van Heerebeek, L.; Hamdani, N.; Edes, I.; Gavina, C.; Leite-Moreira, A.F.; Bronzwaer, J.G.; Papp, Z.; van der Velden, J.; Stienen, G.J.; Paulus, W.J. Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ. Res., 2009, 104(6), 780-786.
23. Kruger, M.; Kotter, S.; Grutzner, A.; Lang, P.; Andresen, C.; Redfield, M.M.; Butt, E.; dos Remedios, C.G.; Linke, W.A. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ. Res., 2009, 104(1), 87-94.
24. Hidalgo, C.; Hudson, B.; Bogomolovas, J.; Zhu, Y.; Anderson, B.; Greaser, M.; Labeit, S.; Granzier, H. PKC phosphorylation of titin's PEVK element: a novel and conserved pathway for modulating myocardial stiffness. Circ. Res., 2009, 105(7), 631-638, 617 p following 638.
25. van Heerebeek, L.; Hamdani, N.; Handoko, M.L.; Falcao-Pires, I.; Musters, R.J.; Kupreishvili, K.; Ijsselmuiden, A.J.; Schalkwijk, C.G.; Bronzwaer, J.G.; Diamant, M.; Borbely, A.; van der Velden, J.; Stienen, G.J.; Laarman, G.J.; Niessen, H.W.; Paulus, W.J. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation, 2008, 117(1), 43-51.
26. Rubler, S.; Dlugash, J.; Yuceoglu, Y.Z.; Kumral, T.; Branwood, A.W.; Grishman, A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol., 1972, 30(6), 595-602.
27. Zarich, S.W.; Arbuckle, B.E.; Cohen, L.R.; Roberts, M.; Nesto, R.W. Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J. Am. Coll. Cardiol., 1988, 12(1), 114-120.
28. nd ed.; Crawford, M.H.; DiMarco, J.P.; Paulus, W.J. Eds.; Mosby: Edinburgh, 2004; pp. 980-981.
29. rd ed.; Crawford, M.H.; DiMarco, J.P. Paulus, W.J. Eds.; Mosby: London, 2009; pp. 1107-1109.
30. van Heerebeek, L.; Somsen, A.; Paulus, W.J. The failing diabetic heart: focus on diastolic left ventricular dysfunction. Curr. Diab. Rep., 2009, 9(1), 79-86.
31. MacDonald, M.R.; Petrie, M.C.; Varyani, F.; Ostergren, J.; Michelson, E.L.; Young, J.B.; Solomon, S.D.; Granger, C.B.; Swedberg, K.; Yusuf, S.; Pfeffer, M.A.; McMurray, J.J. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur. Heart. J., 2008, 29(11), 1377-1385.
32. Stone, P.H.; Muller, J.E.; Hartwell, T.; York, B.J.; Rutherford, J.D.; Parker, C.B.; Turi, Z.G.; Strauss, H.W.; Willerson, J.T.; Robertson, T.; et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J. Am. Coll. Cardiol., 1989, 14(1), 49-57.
33. Solomon, S.D.; St John Sutton, M.; Lamas, G.A.; Plappert, T.; Rouleau, J.L.; Skali, H.; Moye, L.; Braunwald, E.; Pfeffer, M.A. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation, 2002, 106(10), 1251-1255.
34. Ikonomidis, I.; Tsoukas, A.; Parthenakis, F.; Gournizakis, A.; Kassimatis, A.; Rallidis, L.; Nihoyannopoulos, P. Four year follow up of aortic valve replacement for isolated aortic stenosis: a link between reduction in pressure overload, regression of left ventricular hypertrophy, and diastolic function. Heart, 2001, 86(3), 309-316.
35. Rajamannan, N.M.; Gersh, B.; Bonow, R.O. Calcific aortic stenosis: from bench to the bedside--emerging clinical and cellular concepts. Heart, 2003, 89(7), 801-805.
36. Hess, O.M.; Ritter, M.; Schneider, J.; Grimm, J.; Turina, M.; Krayenbuehl, H.P. Diastolic stiffness and myocardial structure in aortic valve disease before and after valve replacement. Circulation, 1984, 69(5), 855-865.
37. th ed., DiPiro, J.T.; Talbert, R.L.; Yee, G.C.; Matzke, G.R.; Wells, B.G.; Posey, L.M. Eds.; McGraw-Hill: New York, 2005; pp. 357-372.
38. Marian, A. Recent advances in genetics and treatment of hypertrophic cardiomyopathy. Future Cardiol., 2005, 1(3), 341-353.
39. Abozguia, K.; Nallur-Shivu, G.; Phan, T.T.; Ahmed, I.; Kalra, R.; Weaver, R.A.; McKenna, W.J.; Sanderson, J.E.; Elliott, P.; Frenneaux, M.P. Left ventricular strain and untwist in hypertrophic cardiomyopathy: relation to exercise capacity. Am. Heart J., 2010, 159(5), 825-832.
40. Dong, S.J.; Hees, P.S.; Siu, C.O.; Weiss, J.L.; Shapiro, E.P. MRI assessment of LV relaxation by untwisting rate: a new isovolumic phase measure of tau. Am. J. Physiol. Heart Circ. Physiol., 2001, 281(5), H2002-2009.
41. Morimoto, S. Sarcomeric proteins and inherited cardiomyopathies. Cardiovasc. Res., 2008, 77(4), 659-666.
42. van Dijk, S.J.; Dooijes, D.; dos Remedios, C.; Michels, M.; Lamers, J.M.; Winegrad, S.; Schlossarek, S.; Carrier, L.; ten Cate, F.J.; Stienen, G.J.; van der Velden, J. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation, 2009, 119(11), 1473-1483.
43. Marian, A.J. Clinical and Molecular Genetic Aspects of Hypertrophic Cardiomyopathy. Curr. Cardiol. Rev., 2005, 1(1), 53-63.
44. th ed.; Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., Kinzler, K.E., Vogelstein, B., Eds.; McGraw-Hill: New York, 2001; pp. 3733-3774.
45. Weidemann, F.; Breunig, F.; Beer, M.; Sandstede, J.; Stork, S.; Voelker, W.; Ertl, G.; Knoll, A.; Wanner, C.; Strotmann, J.M. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur. Heart J., 2005, 26(12), 1221-1227.
46. Pieroni, M.; Chimenti, C.; Ricci, R.; Sale, P.; Russo, M.A.; Frustaci, A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation, 2003, 107(15), 1978-1984.
47. Chimenti, C.; Hamdani, N.; Boontje, N.M.; DeCobelli, F.; Esposito, A.; Bronzwaer, J.G.; Stienen, G.J.; Russo, M.A.; Paulus, W.J.; Frustaci, A.; van der Velden, J. Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease. Am. J. Pathol., 2008, 172(6), 1482-1490.